The Glucose Transporter 5 Enhances CAR-T Cell Metabolic Function and Anti-tumour Durability
Roddy S. O’Connor(University of Pennsylvania), Saar Gill(California University of Pennsylvania), Simon Heeke(The University of Texas MD Anderson Cancer Center), Andre Kelly(University of Pennsylvania), Feng Shen(Tongde Hospital of Zhejiang Province), Nicholas Jones(University of Bristol), Nathaniel W. Snyder, Adam Chatoff(Temple University), Alison Jaccard(Cancer Research Institute of the Slovak Academy of Sciences), John Scholler(University of Pennsylvania), Claudia V. Crispim(Temple University), Bakir Valentić(University of Pennsylvania), Alexander A. Shestov(California University of Pennsylvania), Zhiyang Gan(University of Pennsylvania), Saba Ghassemi(University of Pennsylvania)
Cited by 5
Related Papers
The Changing Epidemiology of Autism Spectrum Disorders
|Annual Review of Public Health|2017|1k
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930
Targeting cardiac fibrosis with engineered T cells
|Nature|2019|792
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
|Journal of Clinical Investigation|2016|554
Metabolic and epigenetic regulation of T-cell exhaustion
|Nature Metabolism|2020|443